Impact of multiplexed genotyping and histology techniques for cancer biomarker discovery

3^rd International Conference on Genomics & Pharmacogenomics

September 21-23, 2015 San Antonio, USA

Darrell R Borger

Harvard University, USA

Posters-Accepted Abstracts: J Mol Genet Med

Abstract :

Our laboratory has performed clinical genotyping for over the past 5 years in a large academic hospital setting in order to provide a rational direction for directing treatment to our cancer patients. We have tested ~9,000 cancer patients clinically using our first generation platform and have acquired data on how this has expanded clinical utility through accrual in targeted therapy trials. Opportunities have been provided for both common malignancies such as breast cancer and rare malignancies such as bile duct cancer. Over the last year, we have converted testing to a next generation sequencing platform. Early benefits include the ability to identify a much more diverse mutational profile. One area of particular excitement is the insight that has been provided regarding tumor heterogeneity and how that may impact response to targeted therapy. While NGS is a tremendous clinical testing tool, a number of examples will be given on how traditional slide-based techniques can be valuable in putting these results into perspective.

Biography :

Email: dborger1@mgh.harvard.edu